Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Ciardiello F, et al. Among authors: fenizia f. Ann Oncol. 2014 Sep;25(9):1756-1761. doi: 10.1093/annonc/mdu230. Epub 2014 Jun 18. Ann Oncol. 2014. PMID: 24942275 Free article.
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Normanno N, et al. Among authors: fenizia f. Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851630 Free article. Clinical Trial.
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.. Pinto C, et al. Among authors: fenizia f. Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30. Future Oncol. 2018. PMID: 29846100 Clinical Trial.
Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P, Roma C, Cozzolino S, Fenizia F, Rachiglio AM, Tatangelo F, Iannaccone A, Baron L, Botti G, Normanno N. Carotenuto P, et al. Among authors: fenizia f. Int J Oncol. 2012 Feb;40(2):378-84. doi: 10.3892/ijo.2011.1221. Epub 2011 Oct 4. Int J Oncol. 2012. PMID: 21971641
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N, Vitagliano D, Morgillo F, Fenizia F, Lambiase M, Formisano L, Bianco R, Ciardiello D, Ciardiello F. Troiani T, et al. Among authors: fenizia f. Clin Cancer Res. 2015 Sep 15;21(18):4153-64. doi: 10.1158/1078-0432.CCR-15-0211. Epub 2015 May 27. Clin Cancer Res. 2015. PMID: 26019172
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V, Botti G, Maiello E, Normanno N. Roma C, et al. Among authors: fenizia f. Cancer Biol Ther. 2016 Aug 2;17(8):840-8. doi: 10.1080/15384047.2016.1195048. Cancer Biol Ther. 2016. PMID: 27261210 Free PMC article.
Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, Nappi A, Iaffaioli RV, Tatangelo F, Botti G, Ciardiello F, Maiello MR, De Luca A, Normanno N. Rachiglio AM, et al. Among authors: fenizia f. Oncotarget. 2016 Oct 11;7(41):66595-66605. doi: 10.18632/oncotarget.10704. Oncotarget. 2016. PMID: 27448974 Free PMC article.
Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.
Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Rachiglio AM, et al. Among authors: fenizia f. Cancers (Basel). 2019 Jun 20;11(6):859. doi: 10.3390/cancers11060859. Cancers (Basel). 2019. PMID: 31226844 Free PMC article.
Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.
Pasquale R, Fenizia F, Esposito Abate R, Sacco A, Esposito C, Forgione L, Rachiglio AM, Bevilacqua S, Montanino A, Franco R, Rocco G, Botti G, Denis MG, Morabito A, De Luca A, Normanno N. Pasquale R, et al. Among authors: fenizia f. Pharmacogenomics. 2015;16(10):1135-48. doi: 10.2217/pgs.15.45. Epub 2015 Aug 7. Pharmacogenomics. 2015. PMID: 26249748
29 results